Rexahn Receives a Notice of Allowance from the U.S. Patent & Trademark Office for a Novel Targeted Cancer Drug Delivery Platf...
September 03 2014 - 9:00AM
Business Wire
Company expands its pipeline of breakthrough
drug delivery technologies designed to improve the efficacy and
safety of widely used FDA-approved anti-cancer drugs
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage
biopharmaceutical company developing best-in-class therapeutics for
the treatment of cancer, today announced it has received a notice
of allowance from the United States Patent and Trademark Office for
a new delivery technology titled, “Polymeric Systems for the
Delivery of Anticancer Drugs”. The patent covers CPMA, a new
polymer drug delivery platform technology developed by Rexahn.
“We are pleased to further expand our platform of proprietary
drug delivery technologies in preclinical development. CPMA
complements our nano-polymer-drug delivery platform,
nano-polymer-drug conjugate system (NPDCS), which has already shown
promising results in preclinical studies,” stated Rexahn’s CEO,
Peter D. Suzdak, Ph.D. “Our drug delivery platforms address a
well-recognized need in cancer treatment for drugs that selectively
target and kill cancer cells, while leaving healthy cells unharmed.
Although numerous widely used FDA-approved anti-cancer drugs offer
benefits to patients, in most cases, the efficacy of these drugs
can be significantly improved, and their toxic side-effects
minimized, if they can be combined with a targeted drug delivery
technology to bring the drug directly into cancer cells.”
The CPMA technology platform allows for multiple anti-cancer
compounds to be covalently bound to the proprietary polymer
backbone and be coupled to a signaling moiety. The signaling moiety
directs the bound drug to the cancer cell, thereby bypassing
healthy cells leading to enhanced efficacy with the potential for
reduced side effects. Once inside the cancer cell the CPMA complex
is metabolized yielding the free anticancer compound. Because of
its diverse chemical properties, CPMA is highly water soluble which
allows water insoluble anti-cancer compounds to be bioavailable
through a more effective delivery.
About Rexahn’s Proprietary Drug Delivery Platforms
CPMA is a polymer based drug delivery platform for the
targeted delivery of anticancer compounds directly to cancer cells.
The highly versatile chemical properties of CPMA allow it to be
covalently linked to a diverse range of anti-cancer compounds
together with a signaling moiety directing it to cancer cells and
bypassing healthy tissues. Once inside a cancer cell covalent
linker is metabolized yielding the free anti-cancer compound. CPMA
has the flexibility to covalently bind multiple anti-cancer
compounds into a signal formulation. Because it is highly water
soluble, CPMA also enables compounds that are water insoluble to be
more effectively delivered and bioavailable.
NPDCS is a nano-polymer targeted anticancer drug delivery
platform. Rexahn’s first clinical candidate for NPDCS is RX-21101,
which combines its nano-drug delivery system with docetaxel, a
widely used FDA approved chemotherapeutic agent. RX-21101 may
bolster efficacy while lowering toxicity of docetaxel and other FDA
approved drugs through specific tumor targeting and improved
deliver to the tumor site. Potential indications include breast,
ovarian, prostate and lung cancers.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage biopharmaceutical
company dedicated to developing best-in-class therapeutics for the
treatment of cancer. Rexahn currently has three clinical stage
oncology candidates, Archexin®, RX-3117, and SupinoxinTM (RX-5902)
and a robust pipeline of preclinical compounds to treat multiple
types of cancer. Rexahn has also developed proprietary drug
discovery platform technologies in the areas of Nano-Polymer-Drug
Conjugate Systems (NPDCS), CPMA, 3D-GOLD, and TIMES. For more
information, please visit www.rexahn.com.
Safe Harbor
To the extent any statements made in this press release deal
with information that is not historical, these are forward-looking
statements under the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about Rexahn’s plans, objectives, expectations and intentions with
respect to future operations and products and other statements
identified by words such as “will,” “potential,” “could,” “can,”
“believe,” “intends,” “continue,” “plans,” “expects,”
“anticipates,” “estimates,” “may,” other words of similar meaning
or the use of future dates. Forward-looking statements by their
nature address matters that are, to different degrees, uncertain.
Uncertainties and risks may cause Rexahn’s actual results to be
materially different than those expressed in or implied by Rexahn’s
forward-looking statements. For Rexahn, particular uncertainties
and risks include, among others, the difficulty of developing
pharmaceutical products, obtaining regulatory and other approvals
and achieving market acceptance; the marketing success of Rexahn’s
licensees or sublicensees; the success of clinical testing; and
Rexahn’s need for and ability to obtain additional financing. More
detailed information on these and additional factors that could
affect Rexahn’s actual results are described in Rexahn’s filings
with the Securities and Exchange Commission, including its most
recent annual report on Form 10-K and subsequent quarterly reports
on Form 10-Q. All forward-looking statements in this news release
speak only as of the date of this news release. Rexahn undertakes
no obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
The Trout Group, LLCTricia Trueheart,
646-378-2953ttrueheart@troutgroup.com
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rexahn Pharmaceuticals, Inc. (AMEX:RNN)
Historical Stock Chart
From Apr 2023 to Apr 2024